載入...
Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
BACKGROUND: Comparisons of second‐line anti‐tumour necrosis factor (TNF) agents and vedolizumab are sparse. AIM: To evaluate the effectiveness of anti‐TNF agents compared to vedolizumab as second‐line biologics in inflammatory bowel disease (IBD). METHODS: A propensity score‐matched cohort was creat...
Na minha lista:
| 發表在: | Aliment Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7898922/ https://ncbi.nlm.nih.gov/pubmed/33340426 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.16193 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|